Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014087
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company’s product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the treatment of acute respiratory distress syndrome (ARDS) an orphan lung disease. Faron’s drug platform traumakine prevents vascular leakage through the injured endothelium of several central organs. Its pipeline products concentrates on the therapeutic areas of acute organ traumas, cancer immunotherapy and vascular damage. The company also works in collaboration with academic institutions. Faron Pharma is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Faron Pharmaceuticals Oy, Medical Devices Deals, 2011 to YTD 2017 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Faron Pharma Enters Into Licensing Agreement With Maruishi Pharma For Traumakine 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 13
Faron Pharma Enters into Agreement with Selexis 14
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 15
Licensing Agreements 16
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 16
China Medical System Enters into Licensing Agreement with Faron Pharma 17
Equity Offering 18
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 18
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 19
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 20
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 21
Faron Pharma Raises USD6 Million in Private Placement of Shares 22
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 23
Faron Pharma Raises Funds in IPO 25
Acquisition 26
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 26
Faron Pharmaceuticals Oy – Key Competitors 27
Faron Pharmaceuticals Oy – Key Employees 28
Faron Pharmaceuticals Oy – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Sep 06, 2017: Faron Pharmaceuticals: Interim Results for the six months ended 30 June 2017 30
Mar 29, 2017: Faron Pharmaceuticals: Final Results for the year ended 31 December 2016 32
Feb 09, 2017: Faron update for 2017 38
Sep 05, 2016: Faron Pharmaceuticals Announces Interim Results for the six months ended 30 June 2016 39
Mar 10, 2016: Faron Pharmaceuticals: Annual Results for the year ended 31 December 2015 40
Corporate Communications 41
Apr 19, 2017: Faron Pharmaceuticals: Proposed Board Changes 41
Product News 42
06/14/2016: Faron Provides Update On Clevegen at R&D Day 42
06/14/2016: Faron Provides Update on Traumakine at R&D Day 43
05/26/2016: Faron Expands R&D Strategy for Novel Immunotherapy Drug Candidate, Clevegen 44
Clinical Trials 45
Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial 45
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Faron Pharmaceuticals Oy, Deals By Therapy Area, 2011 to YTD 2017 9
Faron Pharmaceuticals Oy, Medical Devices Deals, 2011 to YTD 2017 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Faron Pharma Enters Into Licensing Agreement With Maruishi Pharma For Traumakine 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 13
Faron Pharma Enters into Agreement with Selexis 14
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 15
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 16
China Medical System Enters into Licensing Agreement with Faron Pharma 17
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 18
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 19
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 20
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 21
Faron Pharma Raises USD6 Million in Private Placement of Shares 22
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 23
Faron Pharma Raises Funds in IPO 25
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 26
Faron Pharmaceuticals Oy, Key Competitors 27
Faron Pharmaceuticals Oy, Key Employees 28

★海外企業調査レポート[Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sir Robert McAlpine Ltd:企業の戦略的SWOT分析
    Sir Robert McAlpine Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Medical Facilities Corp (DR):製薬・医療:M&Aディール及び事業提携情報
    Summary Medical Facilities Corp (MFC) is a healthcare service provider that provides inpatient and outpatient surgical procedures. The hospital offers surgical equipment, non-surgical professional services, drugs and supplies, and other support services. Its specialty surgical division performs non- …
  • TAT Technologies, Ltd.:企業の戦略・SWOT・財務分析
    TAT Technologies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary TAT Technologies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Resverlogix Corp (RVX)-製薬・医療分野:企業M&A・提携分析
    Summary Resverlogix Corp (Resverlogix) is an epigenetics company that develops small molecule therapeutics for Bromodomain and ExtraTerminal Domain (BET) inhibition. The company provides lead product such as RVX-208 (apabetalone), is a BET inhibitor under phase III clinical trial. Its RVX-208 is bei …
  • Vyriad Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Vyriad Inc (Vyriad), formerly Omnis Pharma Inc is a clinical stage bio-pharmaceutical company that develops viral-based novel oncolytic therapies for the treatment of cancer. The company’s pipeline products include various engineered viruses in phase 1 for the treatment of non small cell lun …
  • Volex plc (VLX):企業の財務・戦略的SWOT分析
    Volex plc (VLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • FunPep Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary FunPep Co Ltd (FunPep) is a biotechnology venture company that focuses on the development of peptides. The company’s pipeline products include SR-0379 functional peptide and FPP003 antibody inducing peptide. It uses smart peptide research integrated technology for developing functional pepti …
  • Embera NeuroTherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Embera NeuroTherapeutics Inc (Embera) is a contract research company that discovers and develops new treatments. The company’s product includes EMB-001, a drug combination for the stress response system and specific brain functions that results in craving and improvement associated with thes …
  • Edward Don & Company:企業の戦略・SWOT・財務情報
    Edward Don & Company - Strategy, SWOT and Corporate Finance Report Summary Edward Don & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sharp Corporation:企業の戦略・SWOT・財務情報
    Sharp Corporation - Strategy, SWOT and Corporate Finance Report Summary Sharp Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Enlivant Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Enlivant Inc (Enlivant) is an assisted living facilities provider that offers senior living residence services. The center provides senior housing options, choosing assisted living and short term stay services. It also provides attentive and individualized care services. Enlivant offers assi …
  • Biomatlante SA:企業の製品パイプライン分析
    Summary Biomatlante SA (Biomatlante) operates as a biologics solutions provider that manufactures, develops, and commercializes synthetic bone graft technologies and synthetic biomaterials for bone regeneration. The company’s products include inserts, granules, sticks, wedges, syringes, putty, screw …
  • ERG SpA (ERG)-エネルギー分野:企業M&A・提携分析
    Summary ERG S.p.A. (ERG), a subsidiary of San Quirico S.P.A., is a diversified energy company. Through its subsidiaries, it conducts power generation through renewable and thermal sources. The company carries out the distribution and marketing of petroleum products and conducts refining activities. …
  • Verbund AG:企業の発電所・SWOT分析2018
    Verbund AG - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Country Club Hospitality & Holidays Ltd.
    Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report Summary Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Valecha Engineering Ltd:企業の戦略・SWOT・財務情報
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Instituto Costarricense de Electricidad:企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Tata Consultancy Services Limited:戦略・SWOT・企業財務分析
    Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Consultancy Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • BJ’s Wholesale Club Inc:企業の戦略・SWOT・財務分析
    BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report Summary BJ's Wholesale Club Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BELLUS Health Inc (BLU)-製薬・医療分野:企業M&A・提携分析
    Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second ind …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆